GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » Balance Sheet Cash And Cash Equivalents

Viridian Therapeutics (STU:1S1) Balance Sheet Cash And Cash Equivalents


View and export this data going back to 2017. Start your Free Trial

What is Viridian Therapeutics Balance Sheet Cash And Cash Equivalents?

Please go to this page to see Cash And Cash Equivalents for non-financial companies.


Viridian Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).